Investors are taking a fresh look at BridgeBio Pharma Inc. (BBIO) these days. It's one of those biotech stories where a bunch of things seem to be happening at once—regulatory filings are getting closer, new data is coming in, and analysts are starting to pencil in some serious revenue numbers. It's the kind of situation that gets the market buzzing.

The latest nod comes from William Blair, which just decided to start covering the commercial-stage biotech. Analyst John Boyle put out a note saying the company is "in a unique position with an accelerating launch in Attruby, near-term NDA submissions for disease-modifying therapies setting up late-2026/early-2027 launches." In plain English: they've got a drug on the market that's picking up steam, and they've got more shots on goal queuing up for approval soon. Blair slapped an Outperform rating on the stock with a fair value estimate of $93.03 per share.

So, what's all the fuss about? Let's start with the big one: Attruby (acoramidis). It's BridgeBio's treatment for ATTR-CM, a serious heart condition. The market here is already pretty crowded, with Pfizer Inc. (PFE)'s Vyndamax (tafamidis) as the longtime leader and Alnylam Pharmaceutical Inc. (ALNY)'s Amvuttra (vutrisiran) as another newer option. Investors love to debate which drug has the best clinical profile, but Boyle's take is that market surveys show doctors see both Attruby and Amvuttra as next-generation products that are better than the older tafamidis.

Pfizer's drug is still the king, pulling in roughly $6 billion in annualized sales, but the newer treatments are growing fast. The question for BridgeBio is what happens when generics could potentially enter the market in late 2028. William Blair thinks the risk might be overblown. They argue that Attruby's stronger TTR stabilization and its simple twice-daily dosing make a good case for it to keep a premium price, even if cheaper copies show up. The firm is modeling U.S. sales for Attruby to hit $3.4 billion by 2035. That's not small change.

But Attruby isn't the only story. BridgeBio has other irons in the fire for rare diseases. One is infigratinib for achondroplasia (ACH), a form of dwarfism. In February, the company shared positive top-line results from its PROPEL 3 Phase 3 study. The data suggest it could have a best-in-class efficacy profile, and it's a once-daily oral pill. That's a big deal because the current standard, BioMarin Pharmaceutical Plc (BMRN)'s Voxzogo, requires a daily injection. A pill you take once a day is a much easier sell for patients and doctors, giving BridgeBio a meaningful edge if it gets approved. The plan is to file with the FDA in 2026.

Then there's encaleret for autosomal dominant hypocalcemia type 1 (ADH1), a rare calcium disorder. Back in October 2025, BridgeBio's CALIBRATE Phase 3 study met its primary endpoint. So that's another therapy moving through the pipeline with promising data.

Put it all together, and you've got a company with one drug growing its launch, two more with strong late-stage data heading toward regulatory submissions, and analysts starting to build financial models around them. It's the kind of pipeline progression that can re-rate a biotech stock.

Investors seemed to like the news. BridgeBio Pharma shares were up 12.60% at $73.91 at the time of publication on Tuesday, according to market data.